Intestinal CD103+CD4+ and CD103+CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up. Issue 9 (27th March 2019)

• Record Type: Journal Article
• Authors: Roosenboom, Britt; Wahab, Peter J; Smids, Carolijn; Groenen, Marcel J M; van Koolwijk, Elly; van Lochem, Ellen G; Horjus Talabur Horje, Carmen S
• Is Part Of: Inflammatory bowel diseases. Volume 25:Issue 9(2019)
• Page Start: 1497
• Page End: 1509
• Publication Date: 2019-03-27
• Subjects: IBD -- CD103 -- translational immunology -- CD69; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izz049
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: The integrin CD103 is proposed to be a potential therapeutical target in inflammatory bowel disease (IBD), as it can form a heterodimeric integrin with β7 (Etrolizumab, anti-β7 integrin) on epithelial T cells. Therefore, we aimed to study the frequencies of different intestinal CD103 + T-cell subsets, both CD4 + and CD8 +, in newly diagnosed, untreated IBD patients at baseline and during follow-up, compared with healthy controls. Methods: Intestinal biopsies from inflamed segments during colonoscopy and peripheral blood samples were prospectively taken from IBD patients at diagnosis and during follow-up. Blood and single cell suspensions from biopsies were analyzed for CD103 + T-cell subpopulations by flow cytometry and expressed as median percentages of the total T-cell population. Results: In total, 75 Crohn's disease (CD) patients, 49 ulcerative colitis (UC) patients, and 16 healthy controls were included. At presentation, IBD patients displayed lower percentages of CD103 + T-cell subsets in inflamed biopsies: 3% (1 to 5) CD103 + CD4 + in IBD vs 5% (5 to 7) in healthy controls ( P = 0.007) and 9% (4 to 15) CD103 + CD8 + compared with 42% (23 to 57) in healthy controls ( P = 0.001). The majority of intestinal T cells was composed of CD103 - CD4 + T cells (65% [52 to 74]) in IBD compared with 30% (21 to 50) in healthy controls ( P = 0.001). In patients with endoscopic remission during follow-up (n = 27), frequencies of CD103 + and CD103 - T-cell subsets were comparable with healthy controls. Conclusion: At diagnosis, active inflammation in IBD was associated with decreased percentages of both CD103 + CD4 + and CD103 + CD8 + T-cell subsets in colon and ileum biopsies. In active disease during follow-up, these T-cell populations remained low but increased in remission to values comparable with healthy controls. A shift toward more CD103 - T cells was observed during active inflammation. Abstract : With the upcoming anti-β7 therapies, the frequencies of the targeted CD103+CD4+ and CD103+CD8+T-cell populations were studied in newly diagnosed, untreated IBD patients at diagnosis and during follow-up. In active disease, these T-cell populations remained low but increased in remission.